Aquestive Therapeutics (AQST) Profit After Tax (2017 - 2026)

Aquestive Therapeutics has reported Profit After Tax for 10 years, with the latest figure at -$22.9 million in Q2 2026.

• On a quarterly basis, Profit After Tax fell 68.76% year-over-year to -$22.9 million in Q2 2026; TTM through Jun 2026 was -$78.2 million, a 20.27% decrease from a year earlier, with the FY2025 full-year figure at -$83.8 million, down 89.83% from the prior year.
• Profit After Tax was -$22.9 million for Q2 2026 at Aquestive Therapeutics, down from -$8.1 million in the prior quarter.
• The five-year high for Profit After Tax was $8.1 million in Q1 2023, with the low at -$31.9 million in Q4 2025.
• Average Profit After Tax over 5 years is -$12.3 million, with a median of -$12.7 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax soared 161.03% in 2023, then tumbled 465.55% in 2024.
• Over 5 years, Profit After Tax stood at -$12.4 million in 2022, then surged by 34.33% to -$8.1 million in 2023, then tumbled by 110.27% to -$17.1 million in 2024, then slumped by 86.81% to -$31.9 million in 2025, then grew by 28.24% to -$22.9 million in 2026.
• The last three Profit After Tax figures came in at -$22.9 million (Q2 2026), -$8.1 million (Q1 2026), and -$31.9 million (Q4 2025), per Business Quant data.